Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.

ABSTRACT:

Introduction

PERLA is a global, double-blind, phase II trial comparing anti-programmed cell death protein 1 antibodies, dostarlimab, and pembrolizumab in combination with chemotherapy (D+CT and P+CT, respectively) in patients with metastatic nonsquamous NSCLC without actionable genomic aberrations in the first-line setting.

Methods

Patients were randomized 1:1 to receive not more than 35 cycles of 500 mg dostarlimab or 200 mg pembrolizumab, with less than or equal to 35 cycles of 500 mg/m² pemetrexed and less than or equal to 4 cycles of cisplatin (75 mg/m²) or carboplatin (area under the curve 5 mg/mL/min) every 3 weeks. The primary end point was the overall response rate by blinded independent central review. The secondary end points included progress

SUBMITTER: Lim SM 

PROVIDER: S-EPMC12509971 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature